Pfizer Reports First-Quarter 2011 Results
- Details
- Category: Pfizer
First-quarter 2011 revenues were $16.5 billion, consistent with the year-ago quarter. Revenues for first-quarter 2011 compared with the year-ago quarter were favorably impacted by $97 million, or 1%, due to foreign exchange, and $224 million, or 1%, due to the addition of legacy King products.
Bayer off to a successful start to 2011
- Details
- Category: Bayer
Sales of the Bayer Group climbed by 13.2 percent in the first quarter of 2011, to EUR 9,415 million (Q1 2010: EUR 8,316 million). Adjusted for currency and portfolio effects, sales were up by 10.4 percent.
Pfizer Announces Top-Line Results of Final Two Pivotal Phase 3 Trials of Tofacitinib (CP-690,550)
- Details
- Category: Pfizer
Pfizer Inc. announced top-line results from the ORAL Standard (A3921064) and ORAL Step (A3921032) Phase 3 studies of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor.
Bristol-Myers Squibb Delivers Excellent First Quarter with YERVOY™ (ipilimumab) Approval
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) announced first quarter results that included strong sales and earnings growth, and several key R&D milestones - most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.
Genzyme Revenues Grow in First-Quarter 2011
- Details
- Category: Genzyme
Genzyme Corporation announced that its first-quarter 2011 revenue grew 7 percent compared with the same period in 2010. Genzyme first-quarter revenue grew to $1.009 billion from $941.9 million in the first quarter of 2010.
Shire delivers a strong first quarter performance
- Details
- Category: Shire
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces results for the three months to March 31, 2011.
Lilly and Medtronic Announce Drug-Device Collaboration for Parkinson's Disease
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) have entered into a collaboration to research and develop a new approach to treating Parkinson's disease that involves delivering a potential new medicine to the brain using an implantable drug delivery system.
More Pharma News ...
- Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005
- Bayer affirms the positive benefit-risk profile of its drospirenone- containing oral contraceptives
- Lundbeck's partner Mochida receives approval of Lexapro in Japan
- Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851
- Amgen's First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
- Abbott Reports 17.4 Percent Sales Growth
- Novartis makes strong start for the year